NMP : Vaquez , Thrombocythémie essentielle, Métaplasie myéloide

  • Accueil
  • NMP : Vaquez , Thrombocythémie essentielle, Métaplasie myéloide
  • METER

TITRE (EN) A Multi-Country, Real-World Study to Explore Treatment Patterns, Effectiveness and Healthcare Resource Utilization for Patients Diagnosed With Myelofibrosis Through Chart Review
PROTOCOLE ID METER
CLINICAL TRIAL.gov ID NCT05444972
TYPE(S) DE CANCER NMP : Vaquez , Thrombocythémie essentielle, Métaplasie myéloide
PHASE Autres
TYPE D'ÉTUDE Autre
INSTITUTION CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
5415 boul. de l'Assomption
(514) 252-3400
VILLE Montréal
INVESTIGATEUR(RICE) PRINCIPAL(E) Natasha Szuber
COORDONATEUR(RICE)
STATUT  Actif en recrutement
CRITÈRES D'ÉLIGIBILITÉ (EN)
  • Treated for myelofibrosis (MF) [primary myelofibrosis (PMF) and secondary myelofibrosis (SMF)].
  • Must have initiated their first treatment on or after the first date when ruxolitinib was approved in their country of residence and no later than 31 December 2021.
CRITÈRES D'EXCLUSION (EN)
  • Having received MF treatment in a clinical trial setting.